News

Here you can find the latest TOPADUR news & events.

23.3.2022

Press Release

European Patent Office to Grant TOPADUR’s Patent Application for TOP-N53

The European Patent Office granted a patent covering the lead drug candidate, TOP-N53 used for the treatment of chronic wounds.

15.10.2021

Press Release

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.

5.10.2021

Press Release

TOPADUR Pharma AG announces positive results from a First-in-Human study evaluating the safety, tolerability and efficacy of TOP-N53.

6.7.2021

Press Release

TOPADUR announces the completion of Phase 1 dose escalation study of TOP-N53, a first-in-class wound healing drug candidate.

1.7.2021

Press Release

TOPADUR announces the submission of an application to the European Medicines Agency to receive Orphan Drug Designation Status.

27.5.2021

News

TOPADUR in collaboration with the University Hospital of Zurich and the University of Zurich was awarded CHF 859k by Innosuisse.